(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Inseego Corp., Arcimoto, and Genprex.

The three biggest losers today are Interpace Biosciences, FibroGen, and DouYu.

Winners today

1. Inseego Corp. (INSG) – 23.42%

Inseego Corp. engages in the design and development of fixed and mobile wireless solutions, industrial Internet of Things (IIoT), and cloud solutions for large enterprise verticals, service providers, and small and medium-sized businesses worldwide. The company provides wireless 4G and 5G hardware products for vertical markets, including private LTE/5G networks, First responders network authority/Firstnet, SD-WAN, telematics, remote monitoring and surveillance, and fixed wireless access and mobile broadband devices. Its products include 4G and 5G fixed wireless routers and gateways, mobile hotspots, and wireless gateways and routers for IIoT applications, Gb speed 4G LTE hotspots and USB modems, integrated telematics, and mobile tracking hardware devices, which are supported by applications software and cloud services designed to enable customers to analyze data insights and configure/manage their hardware remotely. The company also sells software-as-a-service (SaaS), software, and services solutions in various mobile and industrial IoT vertical markets comprising fleet management, vehicle telematics, stolen vehicle recovery, asset tracking, monitoring, business connectivity, and subscription management. Its SaaS delivery platforms include Ctrack platforms, which provide fleet, vehicle, aviation, asset, and other telematics applications; and Device Management Solutions, a hosted SaaS platform that helps organizations in managing the selection, deployment, and spend of their customers wireless assets by helping them to save money on personnel and telecom expenses. Inseego Corp. was founded in 1996 and is based in San Diego, California.

NASDAQ ended the session with Inseego Corp. rising 23.42% to $0.24 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ dropped 0.07% to $14,241.02, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Inseego Corp. has a trailing twelve months EPS of $-0.44.

Sales Growth

Inseego Corp.’s sales growth is negative 23.3% for the ongoing quarter and negative 16.7% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Inseego Corp.’s EBITDA is 0.8.

Moving Average

Inseego Corp.’s worth is way below its 50-day moving average of $0.36 and way below its 200-day moving average of $0.65.

More news about Inseego Corp..

2. Arcimoto (FUV) – 23.29%

Arcimoto, Inc. designs, develops, manufactures, sells, and rents three-wheeled electric vehicles in the United States. Its flagship product is the Fun Utility Vehicle (FUV) that delivers a thrilling ride experience comfort for two passengers with cargo, parking, and operation. The company's products also comprise Rapid Responder designed to perform emergency, security, and law enforcement services; Deliverator, an electric last-mile delivery solution to get goods where they need to go; Cameo, an FUV equipped with a rear-facing rear seat and a modified roof built for on-road filming; and Arcimoto Roadster, an unparalleled pure-electric on-road thrill machine. The company was formerly known as WTP Incorporated and changed its name to Arcimoto, Inc. in December 2011. Arcimoto, Inc. was incorporated in 2007 and is headquartered in Eugene, Oregon.

NASDAQ ended the session with Arcimoto jumping 23.29% to $0.78 on Tuesday, after three successive sessions in a row of gains. NASDAQ slid 0.07% to $14,241.02, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Arcimoto has a trailing twelve months EPS of $-15.61.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -165.43%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Arcimoto’s EBITDA is -1.9.

Volume

Today’s last reported volume for Arcimoto is 107007 which is 27.89% above its average volume of 83671.

More news about Arcimoto.

3. Genprex (GNPX) – 8.4%

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

NASDAQ ended the session with Genprex jumping 8.4% to $0.28 on Tuesday, following the last session’s upward trend. NASDAQ fell 0.07% to $14,241.02, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Genprex has a trailing twelve months EPS of $-0.61.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -158.09%.

More news about Genprex.

4. Roku (ROKU) – 7.7%

Roku, Inc., together with its subsidiaries, operates a TV streaming platform. The company operates in two segments, Platform and Devices. Its streaming platform allows users to find and access TV shows, movies, news, sports, and others. The company also provides digital advertising and related services, including the demand-side ad platform and content distribution services, such as subscription and transaction revenue shares; media and entertainment promotional spending services; premium subscriptions services; video and display advertising services; and sells branded channel buttons on remote controls of streaming device. In addition, it offers billing services; and brand sponsorship and promotions, as well as manufactures, sells, and licenses smart TVs under the Roku TV name. Further, the company provides streaming players, audio products, and smart home products and accessories under the Roku brand name. It offers its products and services through retailers and distributors, as well as directly to customers through its website in the United States, Mexico, Canada, the United Kingdom, Brazil, and Germany. Roku, Inc. was incorporated in 2002 and is headquartered in San Jose, California.

NASDAQ ended the session with Roku jumping 7.7% to $102.24 on Tuesday while NASDAQ fell 0.07% to $14,241.02.

Earnings Per Share

As for profitability, Roku has a trailing twelve months EPS of $-6.19.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.15%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Roku’s EBITDA is 3.62.

Sales Growth

Roku’s sales growth is 11.2% for the present quarter and 16.6% for the next.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 67.6% and 47.8%, respectively.

More news about Roku.

5. Gamida Cell Ltd. (GMDA) – 7.63%

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

NASDAQ ended the session with Gamida Cell Ltd. jumping 7.63% to $0.33 on Tuesday, following the last session’s upward trend. NASDAQ fell 0.07% to $14,241.02, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Gamida Cell Ltd. has a trailing twelve months EPS of $-0.82.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1103.79%.

Yearly Top and Bottom Value

Gamida Cell Ltd.’s stock is valued at $0.33 at 01:32 EST, way below its 52-week high of $2.51 and way higher than its 52-week low of $0.22.

More news about Gamida Cell Ltd..

6. Hall of Fame Resort & Entertainment Company (HOFV) – 7.23%

Hall of Fame Resort & Entertainment Company, a resort and entertainment company, doing business as the Pro Football Hall of Fame. It owns the premier sports, entertainment, and media enterprise surrounding the Pro Football Hall of Fame in Canton, Ohio. The company was founded in 2015 and is headquartered in Canton, Ohio.

NASDAQ ended the session with Hall of Fame Resort & Entertainment Company jumping 7.23% to $3.71 on Tuesday, after two sequential sessions in a row of gains. NASDAQ slid 0.07% to $14,241.02, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Hall of Fame Resort & Entertainment Company has a trailing twelve months EPS of $-12.21.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.38%.

More news about Hall of Fame Resort & Entertainment Company.

7. Canaan (CAN) – 7.14%

Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.

NASDAQ ended the session with Canaan jumping 7.14% to $1.73 on Tuesday, following the last session’s upward trend. NASDAQ fell 0.07% to $14,241.02, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Canaan has a trailing twelve months EPS of $-0.47.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.89%.

More news about Canaan.

8. Future FinTech Group (FTFT) – 7.11%

Future FinTech Group Inc., through its subsidiaries, operates a real-name block chain e-commerce platform that integrates block chain and internet technology in People's Republic of China. It operates through CCM Shopping Mall Membership, Sales of Goods, and Others segments. The company offers Chain Cloud Mall (CCM), an enterprise customer interactive and comprehensive shopping and sales service platform; NONOGIRL, a cross-border e-commerce platform; and DCON, a block chain-based application incubator and a digital payment system. It also engages in the development of block chain-based e-commerce and financial technology; and provides technical services and support for real name and blockchain based assets. The company was formerly known as SkyPeople Fruit Juice, Inc. and changed its name to Future FinTech Group Inc. in June 2017. Future FinTech Group Inc. is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Future FinTech Group jumping 7.11% to $0.75 on Tuesday while NASDAQ slid 0.07% to $14,241.02.

Earnings Per Share

As for profitability, Future FinTech Group has a trailing twelve months EPS of $-0.8.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.54%.

Yearly Top and Bottom Value

Future FinTech Group’s stock is valued at $0.75 at 01:32 EST, way under its 52-week high of $2.19 and way above its 52-week low of $0.33.

More news about Future FinTech Group.

9. Niu Technologies (NIU) – 6.57%

Niu Technologies designs, manufactures, and sells smart electric scooters in the People's Republic of China. The company offers RQi, NQi, MQi, SQi, UQi, and Gova series electric scooters and motorcycles; KQi series one kick-scooters; BQi series e-bikes; and Niu Aero Sports Bicycles. It also provides accessories and spare parts under the NIU brand name comprising scooter accessories, such as raincoats, gloves, knee pads, storage baskets and tail boxes, smart phone holders, backrests, and locks; lifestyle accessories, which includes T-shirts, coats, sweaters and hoodies, jeans, hats, bags, jewelry, notebook, badges, key chain, and mugs; and performance upgrade components that comprises of upgraded wheels, shock absorbers, brake calipers, and carbon fiber body panels. In addition, the company, through its NIU app, offers online repair request, DIY repairs, service station locator, theft reporting, smart check, and smart services, as well as NIU cover, which provides insurance services. Niu Technologies sells and services its products through city partners and franchised stores, distributors, and third-party e-commerce platforms and the company's online store. The company was incorporated in 2014 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Niu Technologies rising 6.57% to $2.52 on Tuesday, after two consecutive sessions in a row of losses. NASDAQ dropped 0.07% to $14,241.02, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Niu Technologies has a trailing twelve months EPS of $-0.32.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.94%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Niu Technologies’s EBITDA is 0.02.

Moving Average

Niu Technologies’s value is above its 50-day moving average of $2.43 and way below its 200-day moving average of $3.50.

More news about Niu Technologies.

10. Foresight Autonomous Holdings Ltd. (FRSX) – 6.29%

Foresight Autonomous Holdings Ltd., a technology company, engages in the design, development, and commercialization of sensor systems for the automotive industry in Israel and China. It develops in-line-of-sight vision systems and beyond-line-of-site cellular-based applications. The company offers QuadSight system, a quad-camera multi-spectral vision system for the semi-autonomous and autonomous vehicle market; V2X (vehicle-to-everything), an accident prevention solution based on real-time multi-agents positioning algorithms that enables communication between vehicles, infrastructure, grid, home, and network; and Eye-Net Protect, a cellular-based V2X solution that provides real-time pre-collision alerts to vulnerable road users, such as pedestrians, cyclists, scooter drivers, etc. by using smartphones. It has a strategic cooperation agreement with FLIR Systems, Inc. to develop, market, and distribute QuadSight vision system. The company was formerly known as Asia Development (A.D.B.M.) Ltd. and changed its name to Foresight Autonomous Holdings Ltd. in 2016. Foresight Autonomous Holdings Ltd. was incorporated in 1977 and is headquartered in Ness Ziona, Israel.

NASDAQ ended the session with Foresight Autonomous Holdings Ltd. rising 6.29% to $1.86 on Tuesday while NASDAQ fell 0.07% to $14,241.02.

Earnings Per Share

As for profitability, Foresight Autonomous Holdings Ltd. has a trailing twelve months EPS of $-1.96.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -71.67%.

Moving Average

Foresight Autonomous Holdings Ltd.’s value is above its 50-day moving average of $1.84 and way under its 200-day moving average of $2.40.

Volume

Today’s last reported volume for Foresight Autonomous Holdings Ltd. is 7788 which is 69.01% below its average volume of 25131.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Foresight Autonomous Holdings Ltd.’s EBITDA is -0.87.

More news about Foresight Autonomous Holdings Ltd..

Losers Today

1. Interpace Biosciences (IDXG) – -12.7%

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

NASDAQ ended the session with Interpace Biosciences dropping 12.7% to $1.10 on Tuesday, following the last session’s upward trend. NASDAQ fell 0.07% to $14,241.02, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Interpace Biosciences has a trailing twelve months EPS of $-0.43.

Yearly Top and Bottom Value

Interpace Biosciences’s stock is valued at $1.10 at 01:32 EST, way under its 52-week high of $3.54 and way above its 52-week low of $0.51.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Interpace Biosciences’s EBITDA is 14.54.

More news about Interpace Biosciences.

2. FibroGen (FGEN) – -9.03%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen falling 9.03% to $0.44 on Tuesday while NASDAQ dropped 0.07% to $14,241.02.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.

Volatility

FibroGen’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.96%, a positive 0.06%, and a positive 7.44%.

FibroGen’s highest amplitude of average volatility was 3.94% (last week), 8.27% (last month), and 7.44% (last quarter).

More news about FibroGen.

3. DouYu (DOYU) – -7.6%

DouYu International Holdings Limited, together with its subsidiaries, operates a platform on PC and mobile apps that provides interactive games and entertainment live streaming services in the People's Republic of China. Its platform connects game developers and publishers, professional eSports teams or players and eSports tournament organizers, advertisers, and viewers. The company also sponsors professional players and teams, and organizes eSports tournaments. In addition, it streams other content to include a spectrum of live streaming entertainment options, such as talent shows, music, outdoor, and travel. Further, the company records and offers video clips to allow users to watch replays of selective live streaming content. DouYu International Holdings Limited was founded in 2014 and is headquartered in Wuhan, the People's Republic of China.

NASDAQ ended the session with DouYu falling 7.6% to $0.82 on Tuesday while NASDAQ dropped 0.07% to $14,241.02.

Earnings Per Share

As for profitability, DouYu has a trailing twelve months EPS of $0.03.

PE Ratio

DouYu has a trailing twelve months price to earnings ratio of 27.41. Meaning, the purchaser of the share is investing $27.41 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.86%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, DouYu’s stock is considered to be overbought (>=80).

Revenue Growth

Year-on-year quarterly revenue growth declined by 24.1%, now sitting on 6.35B for the twelve trailing months.

More news about DouYu.

4. Harpoon Therapeutics (HARP) – -7.51%

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

NASDAQ ended the session with Harpoon Therapeutics dropping 7.51% to $11.95 on Tuesday, after two consecutive sessions in a row of losses. NASDAQ slid 0.07% to $14,241.02, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Harpoon Therapeutics has a trailing twelve months EPS of $-8.62.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -284.32%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 88.4% and 71%, respectively.

Moving Average

Harpoon Therapeutics’s value is way higher than its 50-day moving average of $5.82 and way higher than its 200-day moving average of $7.10.

Yearly Top and Bottom Value

Harpoon Therapeutics’s stock is valued at $11.95 at 01:32 EST, way under its 52-week high of $33.55 and way above its 52-week low of $3.11.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Harpoon Therapeutics’s EBITDA is 4.96.

More news about Harpoon Therapeutics.

5. Bionano Genomics (BNGO) – -7.27%

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

NASDAQ ended the session with Bionano Genomics sliding 7.27% to $1.53 on Tuesday, following the last session’s upward trend. NASDAQ slid 0.07% to $14,241.02, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Bionano Genomics has a trailing twelve months EPS of $-7.17.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -113.43%.

Sales Growth

Bionano Genomics’s sales growth is 28.3% for the ongoing quarter and 46.5% for the next.

More news about Bionano Genomics.

6. Greenpro Capital Corp. (GRNQ) – -6.63%

Greenpro Capital Corp. provides financial consulting and corporate services to small and medium-size businesses primarily in Hong Kong, Malaysia, and China. It operates in two segments, Service Business and Real Estate Business. The company offers business consulting and corporate advisory services, including cross-border listing advisory, tax planning, bookkeeping, advisory and transaction, record management, and accounting outsourcing services; and venture capital related education and support services. It is also involved in the acquisition and rental of real estate properties held for investment and sale; and provision of company formation advisory, company secretarial, and financial services. In addition, the company provides corporate advisory services, such as company review, bank loan advisory, and bank products analysis, as well as loan and credit, and insurance brokerage services; and wealth planning, administration, charity, tax and legal, trusteeship and risk management, investment planning and management, and business support services, as well as asset protection and management, consolidation, and performance monitoring services. The company was formerly known as Greenpro, Inc. and changed its name to Greenpro Capital Corp. in May 2015. Greenpro Capital Corp. was founded in 2013 and is headquartered in Hung Hom, Hong Kong.

NASDAQ ended the session with Greenpro Capital Corp. falling 6.63% to $0.90 on Tuesday while NASDAQ dropped 0.07% to $14,241.02.

Earnings Per Share

As for profitability, Greenpro Capital Corp. has a trailing twelve months EPS of $0.36.

PE Ratio

Greenpro Capital Corp. has a trailing twelve months price to earnings ratio of 2.5. Meaning, the purchaser of the share is investing $2.5 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.31%.

Yearly Top and Bottom Value

Greenpro Capital Corp.’s stock is valued at $0.90 at 01:32 EST, way below its 52-week high of $2.75 and way higher than its 52-week low of $0.72.

Moving Average

Greenpro Capital Corp.’s value is below its 50-day moving average of $0.99 and way below its 200-day moving average of $1.42.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Greenpro Capital Corp.’s EBITDA is 1.22.

More news about Greenpro Capital Corp..

7. Xenetic Biosciences (XBIO) – -6.35%

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

NASDAQ ended the session with Xenetic Biosciences falling 6.35% to $3.06 on Tuesday, after two consecutive sessions in a row of losses. NASDAQ fell 0.07% to $14,241.02, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-2.9.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -30.99%.

Sales Growth

Xenetic Biosciences’s sales growth for the current quarter is 39.9%.

Moving Average

Xenetic Biosciences’s value is way under its 50-day moving average of $4.32 and way under its 200-day moving average of $4.24.

More news about Xenetic Biosciences.

8. TherapeuticsMD (TXMD) – -6.23%

TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

NASDAQ ended the session with TherapeuticsMD sliding 6.23% to $2.79 on Tuesday, following the last session’s upward trend. NASDAQ fell 0.07% to $14,241.02, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, TherapeuticsMD has a trailing twelve months EPS of $4.85.

PE Ratio

TherapeuticsMD has a trailing twelve months price to earnings ratio of 0.57. Meaning, the purchaser of the share is investing $0.57 for every dollar of annual earnings.

Volume

Today’s last reported volume for TherapeuticsMD is 7053 which is 64.95% below its average volume of 20128.

More news about TherapeuticsMD.

9. Gevo (GEVO) – -5.93%

Gevo, Inc. operates as a renewable fuels company. It operates through three segments: Gevo, Agri-Energy, and Renewable Natural Gas. The company offers renewable gasoline and diesel, isooctane, isobutanol, sustainable aviation fuel, renewable natural gas, isobutylene, ethanol, and animal feed and protein. The company was formerly known as Methanotech, Inc. and changed its name to Gevo, Inc. in March 2006. Gevo, Inc. was incorporated in 2005 and is headquartered in Englewood, Colorado.

NASDAQ ended the session with Gevo sliding 5.93% to $1.11 on Tuesday, after two sequential sessions in a row of gains. NASDAQ dropped 0.07% to $14,241.02, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Gevo has a trailing twelve months EPS of $-0.3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.22%.

More news about Gevo.

10. Greenlane Holdings (GNLN) – -5.65%

Greenlane Holdings, Inc. sells cannabis accessories, child-resistant packaging, and specialty vaporization products in the United States, Canada, Europe, Australia, and South America. The company provides vaporizers, liquid nicotine, storage solutions, pipes, apparel lines, and consumption accessories, as well as bubblers, rigs, and other smoking and vaporization related accessories and merchandise. It offers its products under the VIBES rolling papers, Pollen Gear, the Marley Natural accessory line, Aerospaced & Groove grinders, K. Haring Glass Collections, Eyce specialty silicone smoking products, and Higher Standards brands. The company also operates e-commerce websites, such as Vapor.com, Higherstandards.com, Aerospaced.com, Canada.vapor.com, Vaposhop.com, and others. It serves smoke shops, dispensaries, and specialty retail stores. The company was founded in 2005 and is headquartered in Boca Raton, Florida.

NASDAQ ended the session with Greenlane Holdings falling 5.65% to $0.50 on Tuesday while NASDAQ slid 0.07% to $14,241.02.

Earnings Per Share

As for profitability, Greenlane Holdings has a trailing twelve months EPS of $-110.96.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -88.1%.

Volume

Today’s last reported volume for Greenlane Holdings is 23633 which is 69.94% below its average volume of 78625.

Yearly Top and Bottom Value

Greenlane Holdings’s stock is valued at $0.50 at 01:32 EST, way under its 52-week high of $6.00 and higher than its 52-week low of $0.48.

More news about Greenlane Holdings.

Stay up to date with our winners and losers daily report